DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Half Year Results
Eckert & Ziegler Back on Track
15.08.2013 / 07:45
---------------------------------------------------------------------
Press release
Eckert & Ziegler Back on Track
Berlin, August 15, 2013. Eckert & Ziegler AG, a specialist in isotope
technology applications for medicine, science and industry (ISIN
DE0005659700) performed much better in April through June than in the first
quarter. Sales increased by 9 % and profit for the period more than
doubled.
At EUR 55.3 million, sales for the first half of the year are, however,
down 4 % year on year due to the weak start to the year. This was largely
due to changes in organic sales. Sales dropped considerably in the
Radiation Therapy segment due to expectedly sluggish sales of tumor
irradiation equipment, the price drops in the prostate implant product
category and the disposal of the unprofitable accessories business. Sales
in the largest segment, Isotope Products, however, were only down minimally
year on year. Overall, there are clear signs of a positive trend for the
second half of the year as the company's order books are full.
At EUR 6.9 million, EBIT in the first half of 2013 is down 31 % year on
year. This is also due to the weak start to the year. In the Environmental
Services segment, governmental price increases resulted in an adjustment in
provisions for environmental restoration. The Radiopharma segment reported
a rise in the share of low-margin sales (merchandise) and fewer development
costs were capitalized. These were offset by extraordinary income in the
Radiation Therapy segment (agreement with Core Oncology to repay a loan)
and in the Isotope Products segment (court ruling on the reimbursement of
disposal costs).
Profits after taxes and minority interests amounted to EUR 4.0 million, or
EUR 0.75 per share, at the end of the first half of the year, down 27 %
year on year. This decline is less than that seen with EBIT due to lower
interest payments and a drop in the tax rate.
The Group expects sales to grow to around EUR 125 million for the financial
year 2013 and net earnings after taxes and minority interests in the sum of
EUR 2.15 per share.
To read the full report please click here:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euz213e.pdf
With around 630 employees the Eckert & Ziegler Group is one of the world's
largest providers of isotope components for radiotherapy and nuclear
medicine.
If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
End of Corporate News
---------------------------------------------------------------------
15.08.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
225958 15.08.2013
DGAP-News: Eckert & Ziegler Back on Track
| Source: EQS Group AG